Table 5.
LncRNA CCAT2 as a diagnostic and prognostic biomarker for female-related cancers
| Diseases | Targeted lncRNA and marker | Expression | Number of cases | Refs. |
|---|---|---|---|---|
| BC | MEG3,NBAT1,NKILA, GAS5, EPB41L4A-AS2, Z38, andBC040587, H19, SPRY4-IT1, XIST, UCA1, AC026904.1, CCAT1, CCAT2, ITGB2-AS, andAK058003 |
downregulated: MEG3, NBAT1, NKILA, GAS5, EPB41L4A-AS2, Z38, andBC040587, upregulated: H19, SPRY4-IT1, XIST, UCA1, AC026904.1, CCAT1, CCAT2, ITGB2-AS, andAK058003 |
30 patients 30 healthy normal |
[135] |
| CC | CCAT2,CA125,SCC | upregulated | 180, 154 in 5 year survival | [64] |
| CC | CCAT2 | upregulated | Thirty pairs of CC tissues and adjacent normal tissues | [30] |
| BC | CCAT2 | upregulated | 67 female patients | [136] |
| BC | CCAT2 | upregulated | 120 | [62] |
| BC | CCAT2 | upregulated | 60 | [94] |
| BC | CCAT2 | upregulated | - | [63] |
| EOC | Ccat2 | upregulated | Two human EOC cell lines (SKOV3, A2780) | [105] |
| BC | CCAT2 | downregulated | - | [98] |
| BC | CCAT2 | upregulated | 100 female patients | [93] |
| EOC | miR-424 | upregulated | 31 cases of EOC patients at Huai’an First People’s Hospital | [28] |
| CESC | CCAT2 | upregulated | 123 specimens | [65] |
| OC | CCAT2 | upregulated | 109 °C and 45 normal ovarian tissue samples | [118] |
| CESC | CCAT2, LINC01133, LINC00511 | upregulated | 115 cases of CESC, 79 cases of CIN and 101 healthy controls | [137] |
| CESC | CCAT2 rs6983267 SNP, MYC | upregulated | 481patients | [138] |
BC: breast cancer; CC: cervical carcinoma; EOC: epithelial ovarian carcinoma; OC: Ovarian cancer; CESC: Cervical Squamous Carcinoma; MEG3: Maternally Expressed 3; NBAT1: Neuroblastoma Associated Transcript 1; NKILA: NF-KappaB Interacting lncRNA; GAS5: Growth arrest-specific 5; SPRY4-IT1: SPRY4 Intronic Transcript 1; XIST: X-inactive specific transcript; UCA1: Urothelial cancer associated 1; ITGB2-AS: Integrin Subunit Beta 2; CIN: Cervical intraepithelial neoplasia